RhumbLine Advisers’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $480K | Sell |
30,016
-3,017
| -9% | -$48.2K | ﹤0.01% | 2706 |
|
|
2025
Q1 | $502K | Sell |
33,033
-2,558
| -7% | -$38.9K | ﹤0.01% | 2575 |
|
|
2024
Q4 | $722K | Buy |
35,591
+718
| +2% | +$14.6K | ﹤0.01% | 2433 |
|
|
2024
Q3 | $897K | Buy |
34,873
+1,634
| +5% | +$42K | ﹤0.01% | 2319 |
|
|
2024
Q2 | $427K | Buy |
33,239
+33,123
| +28,554% | +$426K | ﹤0.01% | 2782 |
|
|
2024
Q1 | $2.66K | Hold |
116
| – | – | ﹤0.01% | 4061 |
|
|
2023
Q4 | $3.04K | Hold |
116
| – | – | ﹤0.01% | 4053 |
|
|
2023
Q3 | $3.27K | Sell |
116
-234
| -67% | -$6.6K | ﹤0.01% | 4042 |
|
|
2023
Q2 | $10.6K | Sell |
350
-3,092
| -90% | -$94K | ﹤0.01% | 3936 |
|
|
2023
Q1 | $65K | Buy |
3,442
+20
| +0.6% | +$378 | ﹤0.01% | 2895 |
|
|
2022
Q4 | $35K | Buy |
3,422
+57
| +2% | +$583 | ﹤0.01% | 2969 |
|
|
2022
Q3 | $88K | Buy |
3,365
+194
| +6% | +$5.07K | ﹤0.01% | 3014 |
|
|
2022
Q2 | $143K | Buy |
3,171
+1,677
| +112% | +$75.6K | ﹤0.01% | 2999 |
|
|
2022
Q1 | $147K | Buy |
1,494
+64
| +4% | +$6.3K | ﹤0.01% | 2824 |
|
|
2021
Q4 | $219K | Buy |
+1,430
| New | +$219K | ﹤0.01% | 2810 |
|